Aldeyra Therapeutics Inc. (ALDX), which is seeking FDA approval for Reproxalap, in the proposed treatment of the signs and symptoms of dry eye disease, is most likely to face disappointment.The FDA decision is due on November 23, 2023.On October 16, 2023, the FDA informed the company that an additional clinical trial is required to meet the efficacy criteria for Reproxalap. Consequently, the company believes that the FDA may not be in a position to grant approval for the New Drug Application on the scheduled date and that there is a possibility of receiving a Complete Response Letter instead.ALDX closed Friday’s trading at $1.47, down 6.37%.